Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What is the scenario

<< Previous

Bullboard Posts

Next >>

Comment by GameChangerBeton May 20, 2021 8:14am

167 Views

Post# 33236382

RE:RE:RE:RE:RE:RE:RE:What is the scenario

My friend, you said, investing in ATE was a mistake, I simply pointed out that maintaining an investment in something that you think is a mistake is not smart.

Continuing to post non articulate posts on stock boards is not going to provide you with any positive changes. It's certainly not going to change the stock price.

Take a step back, re-evaluate your investment, assess your stress tolerance of staying in an investment that's clearly causing you distress, and make a decision that makes sense for you.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security